Nathan J. Dowden - Oct 28, 2021 Form 3 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Operating Officer
Signature
/s/ Jared Cohen, as Attorney-in-fact
Stock symbol
TRDA
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
3
Date filed
10/28/2021, 08:58 PM
Next filing
Mar 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TRDA Common Stock 61.3K Oct 28, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TRDA Stock Options (Right to Buy) Oct 28, 2021 Common Stock 84.8K $1.74 Direct F1
holding TRDA Stock Options (Right to Buy) Oct 28, 2021 Common Stock 46.1K $2.10 Direct F2
holding TRDA Stock Options (Right to Buy) Oct 28, 2021 Common Stock 83K $8.47 Direct F3
holding TRDA Stock Options (Right to Buy) Oct 28, 2021 Common Stock 4.15K $12.52 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option vested and became exercisable on November 4, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2 25% of the shares subject to this option shall vest and become exercisable on August 12, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F3 25% of the shares subject to this option shall vest and become exercisable on March 30, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4 25% of the shares subject to this option shall vest and become exercisable on August 2, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24 - Power of Attorney